Literature DB >> 23055137

Correlation of interferon-inducible chemokine plasma levels with disease severity in systemic sclerosis.

Xiaochun Liu1, Maureen D Mayes, Filemon K Tan, Minghua Wu, John D Reveille, Brock E Harper, Hilda T Draeger, Emilio B Gonzalez, Shervin Assassi.   

Abstract

OBJECTIVE: To measure interferon (IFN)-inducible chemokines in the plasma of patients with systemic sclerosis (SSc) and investigate whether the chemokine levels are correlated with disease severity.
METHODS: Plasma levels of the IFN-inducible chemokines IFNγ-inducible protein 10 (IP-10/CXCL10), IFN-inducible T cell α chemoattractant (I-TAC/CXCL11), and monocyte chemoattractant protein 1 (CCL2) were measured in SSc patients and examined for correlation with the IFN gene expression signature. A composite IFN-inducible chemokine score was generated for chemokines showing a correlation with the IFN gene signature (IP-10 and I-TAC), and this score was compared between 266 patients with SSc enrolled in the Genetics versus Environment in Scleroderma Outcome Study (GENISOS) cohort and 97 matched control subjects. Subsequently, the correlation between the IFN-inducible chemokine score at baseline and markers of disease severity was assessed. In addition, the course of the IFN-inducible chemokine score over time was examined.
RESULTS: The plasma IFN-inducible chemokine score correlated with the IFN gene expression signature, and this score was higher in SSc patients compared to controls. The IFN-inducible chemokine score was also associated with the absence of anti-RNA polymerase III antibodies and presence of anti-U1 RNP antibodies, but not with disease duration, disease type, or other autoantibodies. The chemokine score correlated with concomitantly obtained scores on the Medsger Severity Index for muscle, skin, and lung involvement in SSc, as well as the forced vital capacity, diffusing capacity for carbon monoxide, and creatine kinase levels. The association of the chemokine score with disease severity was independent of the presence of anti-U1 RNP or other potential confounders (age, sex, ethnicity, disease duration, and treatment with immunosuppressive agents). Finally, there was not a significant change in the IFN-inducible chemokine score over time.
CONCLUSION: The IFN-inducible chemokine score is a stable serologic marker of a more severe form of SSc and may be useful for risk stratification of patients, regardless of disease type (limited or diffuse) or duration of disease.
Copyright © 2013 by the American College of Rheumatology.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23055137      PMCID: PMC3687352          DOI: 10.1002/art.37742

Source DB:  PubMed          Journal:  Arthritis Rheum        ISSN: 0004-3591


  30 in total

1.  Signatures of differentially regulated interferon gene expression and vasculotrophism in the peripheral blood cells of systemic sclerosis patients.

Authors:  F K Tan; X Zhou; M D Mayes; P Gourh; X Guo; C Marcum; L Jin; F C Arnett
Journal:  Rheumatology (Oxford)       Date:  2006-01-17       Impact factor: 7.580

2.  Changes in causes of death in systemic sclerosis, 1972-2002.

Authors:  Virginia D Steen; Thomas A Medsger
Journal:  Ann Rheum Dis       Date:  2007-02-28       Impact factor: 19.103

Review 3.  Systemic sclerosis - continuing progress in developing clinical measures of response.

Authors:  Daniel Furst; Dinesh Khanna; Marco Matucci-Cerinic; Philip Clements; Virginia Steen; Janet Pope; Peter Merkel; Ivan Foeldvari; James Seibold; David Pittrow; Richard Polisson; Vibeke Strand
Journal:  J Rheumatol       Date:  2007-05       Impact factor: 4.666

4.  CXCL10 (alpha) and CCL2 (beta) chemokines in systemic sclerosis--a longitudinal study.

Authors:  A Antonelli; C Ferri; P Fallahi; S M Ferrari; D Giuggioli; M Colaci; A Manfredi; S Frascerra; F Franzoni; F Galetta; E Ferrannini
Journal:  Rheumatology (Oxford)       Date:  2008-01       Impact factor: 7.580

5.  Autoantibodies in systemic sclerosis.

Authors:  Virginia D Steen
Journal:  Semin Arthritis Rheum       Date:  2005-08       Impact factor: 5.532

6.  A macrophage marker, Siglec-1, is increased on circulating monocytes in patients with systemic sclerosis and induced by type I interferons and toll-like receptor agonists.

Authors:  Michael R York; Taro Nagai; Alyson J Mangini; Raphaël Lemaire; Jean Maguire van Seventer; Robert Lafyatis
Journal:  Arthritis Rheum       Date:  2007-03

7.  Interferon-alpha does not improve outcome at one year in patients with diffuse cutaneous scleroderma: results of a randomized, double-blind, placebo-controlled trial.

Authors:  C M Black; A J Silman; A I Herrick; C P Denton; H Wilson; J Newman; L Pompon; X Shi-Wen
Journal:  Arthritis Rheum       Date:  1999-02

8.  Combined analysis of monocyte and lymphocyte messenger RNA expression with serum protein profiles in patients with scleroderma.

Authors:  Hangjun Duan; Jo Fleming; David K Pritchard; Lynn M Amon; Jun Xue; Heather A Arnett; Guang Chen; Patricia Breen; Jane H Buckner; Jerry A Molitor; Keith B Elkon; Stephen M Schwartz
Journal:  Arthritis Rheum       Date:  2008-05

9.  Inter and intraobserver variability of total skin thickness score (modified Rodnan TSS) in systemic sclerosis.

Authors:  P Clements; P Lachenbruch; J Siebold; B White; S Weiner; R Martin; A Weinstein; M Weisman; M Mayes; D Collier
Journal:  J Rheumatol       Date:  1995-07       Impact factor: 4.666

10.  Elevated serum levels of interferon-regulated chemokines are biomarkers for active human systemic lupus erythematosus.

Authors:  Jason W Bauer; Emily C Baechler; Michelle Petri; Franak M Batliwalla; Dianna Crawford; Ward A Ortmann; Karl J Espe; Wentian Li; Dhavalkumar D Patel; Peter K Gregersen; Timothy W Behrens
Journal:  PLoS Med       Date:  2006-12       Impact factor: 11.069

View more
  36 in total

1.  Suppression of T Cell Activation and Collagen Accumulation by an Anti-IFNAR1 mAb, Anifrolumab, in Adult Patients with Systemic Sclerosis.

Authors:  Xiang Guo; Brandon W Higgs; Anne C Bay-Jensen; Morten A Karsdal; Yihong Yao; Lorin K Roskos; Wendy I White
Journal:  J Invest Dermatol       Date:  2015-05-20       Impact factor: 8.551

2.  Induction of a type I interferon signature in normal human monocytes by gadolinium-based contrast agents: comparison of linear and macrocyclic agents.

Authors:  P J Wermuth; S A Jimenez
Journal:  Clin Exp Immunol       Date:  2014-01       Impact factor: 4.330

Review 3.  Moving towards a molecular taxonomy of autoimmune rheumatic diseases.

Authors:  Guillermo Barturen; Lorenzo Beretta; Ricard Cervera; Ronald Van Vollenhoven; Marta E Alarcón-Riquelme
Journal:  Nat Rev Rheumatol       Date:  2018-01-24       Impact factor: 20.543

4.  A synthetic TLR3 ligand mitigates profibrotic fibroblast responses by inducing autocrine IFN signaling.

Authors:  Feng Fang; Kohtaro Ooka; Xiaoyong Sun; Ruchi Shah; Swati Bhattacharyya; Jun Wei; John Varga
Journal:  J Immunol       Date:  2013-08-16       Impact factor: 5.422

5.  Proteomic Analysis of Sera from Individuals with Diffuse Cutaneous Systemic Sclerosis Reveals a Multianalyte Signature Associated with Clinical Improvement during Imatinib Mesylate Treatment.

Authors:  D James Haddon; Hannah E Wand; Justin A Jarrell; Robert F Spiera; Paul J Utz; Jessica K Gordon; Lorinda S Chung
Journal:  J Rheumatol       Date:  2017-03-15       Impact factor: 4.666

Review 6.  Evolving insights into the cellular and molecular pathogenesis of fibrosis in systemic sclerosis.

Authors:  Benjamin Korman
Journal:  Transl Res       Date:  2019-02-23       Impact factor: 7.012

7.  Transcriptional and Cytokine Profiles Identify CXCL9 as a Biomarker of Disease Activity in Morphea.

Authors:  Jack C O'Brien; Yevgeniya Byekova Rainwater; Neeta Malviya; Nika Cyrus; Lorenz Auer-Hackenberg; Linda S Hynan; Gregory A Hosler; Heidi T Jacobe
Journal:  J Invest Dermatol       Date:  2017-04-24       Impact factor: 8.551

Review 8.  Biomarkers in rheumatic diseases: how can they facilitate diagnosis and assessment of disease activity?

Authors:  Chandra Mohan; Shervin Assassi
Journal:  BMJ       Date:  2015-11-26

9.  Peripheral blood cytokine and chemokine profiles in juvenile localized scleroderma: T-helper cell-associated cytokine profiles.

Authors:  Kathryn S Torok; Katherine Kurzinski; Christina Kelsey; Jonathan Yabes; Kelsey Magee; Abbe N Vallejo; Thomas Medsger; Carol A Feghali-Bostwick
Journal:  Semin Arthritis Rheum       Date:  2015-06-17       Impact factor: 5.532

Review 10.  What does global gene expression profiling tell us about the pathogenesis of systemic sclerosis?

Authors:  Shervin Assassi; Maureen D Mayes
Journal:  Curr Opin Rheumatol       Date:  2013-11       Impact factor: 5.006

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.